Unknown PHASE4 INTERVENTIONAL 3-arm NCT03168997

Memantine Treatment in Alzheimer's Disease Patients

Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study

Sponsor: Wei Cuibai

Conditions Alzheimer Disease

Interventions Memantine Hydrochloride

Updated 6 times since 2017 Last updated: May 25, 2017 Started: Jul 15, 2017 Primary completion: Sep 30, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Alzheimer Disease, this trial is ongoing. The trial is conducted by Wei Cuibai and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jun 2019 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Jul 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wei Cuibai

Data source: Xuanwu Hospital, Beijing

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.